Dendreon Corporation
(Other OTC/NBB : DNDN)

( )
DNDN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
ABTAbbott Laboratories
-0.84%67.570.8%$524.77m
MDTMedtronic PLC
-2.11%93.900.6%$463.24m
ISRGIntuitive Surgical, Inc.
-3.45%504.262.4%$430.19m
TMOThermo Fisher Scientific Inc.
-1.13%227.111.0%$349.40m
EWEdwards Lifesciences Corporation
-1.22%145.531.2%$333.05m
ALGNAlign Technology, Inc.
-3.18%312.796.3%$299.58m
BSXBoston Scientific Corporation
-2.67%36.531.1%$274.43m
ABMDABIOMED, Inc.
-6.26%362.423.3%$266.21m
BDXBecton, Dickinson and Company
-0.62%238.321.1%$234.73m
SYKStryker Corporation
-2.50%168.771.3%$213.61m
BAXBaxter International Inc.
-1.43%69.461.7%$199.07m
DXCMDexCom, Inc.
-2.90%129.008.5%$160.90m
ZBHZimmer Biomet Holdings, Inc.
-1.54%124.371.7%$125.79m
TNDMTandem Diabetes Care, Inc.
-6.40%36.124.1%$122.21m
WATWaters Corporation
-1.23%185.423.4%$108.92m

Company Profile

Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.